Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The Investigator hypothesize that Dapagliflozin will improve EPC number and function AND
Saxagliptin in addition to Dapagliflozin (additive effect) may improve EPC number and
function even more than Dapa alone, compared to placebo.
The Investigator propose a 3-arm randomized, parallel group, longitudinal study of 16-week
intervention duration. Participants will be randomized to 3 groups:
Group A: Dapa (10 mg) + Saxa Placebo, Enroll n=15, retain n=12 Group B: Dapa (10 mg) + Saxa
(5 mg), Enroll n=15, retain n=12 Group C: Dapa Placebo + Saxa Placebo, Enroll n=15, retain
n=12